The Vicious Cycle of Myostatin Signaling in Sarcopenic Obesity: Myostatin Role in Skeletal Muscle Growth, Insulin Signaling and Implications for Clinical Trials
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The age-related loss of skeletal muscle (sarcopenia) is a major health concern as it is associated with physical disability, metabolic impairments, and increased mortality. The coexistence of sarcopenia with obesity, termed 'sarcopenic obesity', contributes to skeletal muscle insulin resistance and the development of type 2 diabetes, a disease prevalent with advancing age. Despite this knowledge, the mechanisms contributing to sarcopenic obesity remain poorly understood, preventing the development of targeted therapeutics. This article will discuss the clinical and physiological consequences of sarcopenic obesity and propose myostatin as a potential candidate contributing to this condition. A special emphasis will be placed on examining the role of myostatin signaling in impairing both skeletal muscle growth and insulin signaling. In addition, the role of myostatin in regulating muscle-to fat cross talk, further exacerbating metabolic dysfunction in the elderly, will be highlighted. Lastly, we discuss how this knowledge has implications for the design of myostatin-inhibitor clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Mitochondrial dysfunction in the elderly: possible role in insulin resistance
Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro, L., Cline, G. W., & Shulman, G. I. (2003) · Science · doi:10.1126/science.1082889 · Cited by 2,107 · cited 1×
“Age associated skeletal muscle mitochondrial dysfunction is believed to contribute to obesity and declines in insulin sensitivity with aging (37), although the mechanism(s) remain unclear.”
BackgroundHigh Incidence of Metabolically Active Brown Adipose Tissue in Healthy Adult Humans
Saito, M., Okamatsu-Ogura, Y., Matsushita, M., Watanabe, K., Yoneshiro, T., Nio-Kobayashi, J., Iwanaga, T., Miyagawa, M., Kameya, T., Nakada, K., et al. (2009) · Diabetes · doi:10.2337/db09-0530 · Cited by 1,848 · cited 8×
“Current research suggests that elevated levels of myostatin could contribute to this accelerated loss of BAT and/or beige adipocytes.”
BackgroundInfluentialPetrovic, N., Walden, T. B., Shabalina, I. G., Timmons, J. A., Cannon, B., & Nedergaard, J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.053942 · Cited by 1,263 · cited 1×
“It is under these conditions that a third type of fat cell is induced, beige adipocytes (also referred to as brown-like or brite adipocytes) which tend to be located in WAT, but have similar metabolic properties as brown adipocytes, including increased cellular respiration (44).”
BackgroundMoreno-Navarrete, J. M., Ortega, F., Serrano, M., Guerra, E., Pardo, G., Tinahones, F., Ricart, W., & Fernández-Real, J. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2749 · Cited by 788 · cited 1×
“Irisin levels have been reported to be low in obese individuals and type 2 diabetics (51) and irisin has been shown to induce beige cell markers in adipocytes derived from WAT (35) providing convincing evidence that myostatin induced inhibition of this protein may adversely affect fat metabolism in older, obese adults.”
BackgroundMichael, L. F., Wu, Z., Cheatham, R. B., Puigserver, P., Adelmant, G., Lehman, J. J., Kelly, D. P., & Spiegelman, B. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.061035098 · Cited by 663 · cited 1×
“Our group (38) and others (39) have documented the role that PGC-1 has in stimulating mitochondrial biogenesis, preferentially shutting lipids towards oxidation versus storage, and increasing GLUT4 expression.”
BackgroundInsulin resistance and sarcopenia: mechanistic links between common co-morbidities
Cleasby, M. E., Jamieson, P. M., & Atherton, P. J. (2016) · Journal of Endocrinology · doi:10.1530/joe-15-0533 · Cited by 596
Sarcopenic Obesity: The Confluence of Two Epidemics
Roubenoff, R. (2004) · Obesity Research · doi:10.1038/oby.2004.107 · Cited by 453 · cited 2×
“It has been suggested that there is a biological connection between insulin resistance, obesity and sarcopenia (3), although the mechanisms that might explain a common etiology are not yet fully understood (5).”
BackgroundGuo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., & McPherron, A. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004937 · Cited by 402 · cited 6×
“Similarly, elevated myostatin levels have been associated with both obesity (23) and insulin resistance (23-26).”
BackgroundInfluentialDeFronzo, R. A. (1981) · Diabetes Care · doi:10.2337/diacare.4.4.493 · Cited by 389
Increased secretion and expression of myostatin in skeletal muscle from extremely obese women
Hittel, D. S., Berggren, J. R., Shearer, J., Boyle, K., & Houmard, J. A. (2009) · Diabetes · doi:10.2337/db08-0943 · Cited by 324 · cited 3×
“Similarly, elevated myostatin levels have been associated with both obesity (23) and insulin resistance (23-26).”
BackgroundHuh, J. Y., Dincer, F., Mesfum, E., & Mantzoros, C. S. (2014) · International Journal of Obesity · doi:10.1038/ijo.2014.42 · Cited by 309
Shan, T., Liang, X., Bi, P., & Kuang, S. (2013) · The FASEB Journal · doi:10.1096/fj.12-225755 · Cited by 301
Myostatin decreases with aerobic exercise and associates with insulin resistance
HITTEL, D. S., AXELSON, M., SARNA, N., SHEARER, J., HUFFMAN, K. M., & KRAUS, W. E. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181e0b9a8 · Cited by 271 · cited 2×
“Pharmacological injection of myostatin into mice resulted in reduced insulin-stimulated Akt phosphorylation in the gastrocnemius and vastus lateralis, likely contributing to the whole-body insulin resistance also observed (32).”
BackgroundMyostatin Inhibits IGF-I-Induced Myotube Hypertrophy through Akt
Morissette, M. R., Cook, S. A., Buranasombati, C., Rosenberg, M. A., & Rosenzweig, A. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00043.2009 · Cited by 231
Dong, J., Dong, Y., Dong, Y., Chen, F., Mitch, W. E., & Zhang, L. (2016) · International Journal of Obesity · doi:10.1038/ijo.2015.200 · Cited by 212 · cited 3×
“Of interest, myostatin inhibition has been shown to increase skeletal muscle GLUT4 expression in young rodents (34, 36), old mice (40), and double-muscled cattle (myostatin knockout model) (41) compared to controls.”
BackgroundZhang, C., McFarlane, C., Lokireddy, S., Masuda, S., Ge, X., Gluckman, P. D., Sharma, M., & Kambadur, R. (2012) · Diabetologia · doi:10.1007/s00125-011-2304-4 · Cited by 192 · cited 6×
“MEF2C, like PGC-1, is a transcription factor responsible for GLUT4 expression; therefore, it is possible that inhibiting myostatin upregulates key transcription factors responsible for the upregulation of GLUT4.”
BackgroundInfluentialCamporez, J.-P. G., Petersen, M. C., Abudukadier, A., Moreira, G. V., Jurczak, M. J., Friedman, G., Haqq, C. M., Petersen, K. F., & Shulman, G. I. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525795113 · Cited by 184 · cited 1×
“changes in skeletal muscle strength and function were not reported in this previous study; however, a recent study treating old mice with an anti-myostatin antibody (ATA 842) increased insulin-stimulated whole body glucose metabolism, muscle mass, and grip strength (30).”
ResultChang, J. S., Kim, T. H., Nguyen, T. T., Park, K., Kim, N., & Kong, I. D. (2017) · Geriatrics & Gerontology International · doi:10.1111/ggi.13030 · Cited by 166 · cited 1×
“Of particular interest, low irisin has been suggested as a potential marker for sarcopenia (52, 53), in part based on findings that circulating irisin levels are lower in sarcopenic individuals compared to normal controls, and serum irisin is positively associated with grip strength (52).”
BackgroundZhang, C., McFarlane, C., Lokireddy, S., Bonala, S., Ge, X., Masuda, S., Gluckman, P. D., Sharma, M., & Kambadur, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2079-7 · Cited by 158 · cited 9×
“A number of studies have since been conducted providing evidence that myostatin also exerts a negative effect on insulin signaling through the inhibition of Akt phosphorylation (Figure 1) (26, 32, 33).”
BackgroundInfluentialBergen, H. R., Farr, J. N., Vanderboom, P. M., Atkinson, E. J., White, T. A., Singh, R. J., Khosla, S., & LeBrasseur, N. K. (2015) · Skeletal Muscle · doi:10.1186/s13395-015-0047-5 · Cited by 137
Hjorth, M., Pourteymour, S., Görgens, S. W., Langleite, T. M., Lee, S., Holen, T., Gulseth, H. L., Birkeland, K. I., Jensen, J., Drevon, C. A., et al. (2016) · Acta Physiologica · doi:10.1111/apha.12631 · Cited by 83
Research works printed but not linked: 31
- Stenholm, 2008, Sarcopenic obesity: definition, cause and consequences, Curr Opin Clin Nutr Metab Care, 11, 693, 10.1097/MCO.0b013e328312c37d · DOI · Paper page
- Cauley, 2015, An Overview of Sarcopenic Obesity, Curr Opin Clin Nutr Metab Care, 18, 499
- Reaven, 1988, Banting lecture 1988, Role of insulin resistance in human disease, Diabetes, 37, 1595, 10.2337/diab.37.12.1595 · DOI · Paper page
- Garber, 2016, No longer going to waste, Nat Biotechnol, 34, 458, 10.1038/nbt.3557 · DOI
- Kocsis, 2017, Myostatin propeptide mutation of the hypermuscular Compact mice decreases the formation of myostatin and improves insulin sensitivity, Am J Physiol Endocrinol Metab, 312, 150, 10.1152/ajpendo.00216.2016 · DOI
- Sharma, 1999, Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct, J Cell Physiol, 180, 1, 10.1002/(SICI)1097-4652(199907)180:1<1::AID-JCP1>3.0.CO;2-V · DOI · Paper page
- Goodman, 2013, Smad3 induces atrogin-1, inhibits mTOR and protein synthesis, and promotes muscle atrophy in vivo, Mol Endocrinol, 27, 1946, 10.1210/me.2013-1194 · DOI · Paper page
- Yarasheski, 2002, Serum myostatin-immunoreactive protein is increased in 60-92 year old women and men with muscle wasting, J Nutr Health Aging, 6, 343
- Leger, 2008, Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation, Rejuvenation Res, 11, 163, 10.1089/rej.2007.0588 · DOI · Paper page
- Han, 2011, Serum myostatin levels and grip strength in normal subjects and patients on maintenance haemodialysis, Clin Endocrinol (Oxf), 75, 857, 10.1111/j.1365-2265.2011.04120.x · DOI · Paper page
- Patel, 2014, Lean mass, muscle strength and gene expression in community dwelling older men: findings from the Hertfordshire Sarcopenia Study (HSS), Calcif Tissue Int, 95, 308, 10.1007/s00223-014-9894-z · DOI
- Tay, 2015, Sex-specific differences in risk factors for sarcopenia amongst community-dwelling older adults, Age (Dordr), 37, 121, 10.1007/s11357-015-9860-3 · DOI · Paper page
- Hofmann, 2015, Serum concentrations of insulinlike growth factor-1, members of the TGF-beta superfamily and follistatin do not reflect different stages of dynapenia and sarcopenia in elderly women, Exp Gerontol, 64, 35, 10.1016/j.exger.2015.02.008 · DOI
- Ratkevicius, 2011, Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men, J Gerontol A Biol Sci Med Sci, 66, 620, 10.1093/gerona/glr025 · DOI · Paper page
- Borkan, 1983, Age changes in body composition revealed by computed tomography, J Gerontol, 38, 673, 10.1093/geronj/38.6.673 · DOI · Paper page
- Consitt, 2013, Impairments in site-specific AS160 phosphorylation and effects of exercise training, Diabetes, 62, 3437, 10.2337/db13-0229 · DOI · Paper page
- Ryan, 2013, Aerobic exercise + weight loss decreases skeletal muscle myostatin expression and improves insulin sensitivity in older adults, Obesity (Silver Spring), 21, 1350, 10.1002/oby.20216 · DOI · Paper page
- Palsgaard, 2009, Gene expression in skeletal muscle biopsies from people with type 2 diabetes and relatives: differential regulation of insulin signaling pathways, PLoS One, 4, 6575, 10.1371/journal.pone.0006575 · DOI · Paper page
- Milan, 2004, Changes in muscle myostatin expression in obese subjects after weight loss, J Clin Endocrinol Metab, 89, 2724, 10.1210/jc.2003-032047 · DOI · Paper page
- Morissette, 2009, Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt, Am J Physiol Cell Physiol, 297, C1124, 10.1152/ajpcell.00043.2009 · DOI · Paper page
- Tang, 2014, A prepared anti-MSTN polyclonal antibody reverses insulin resistance of diet-induced obese rats via regulation of PI3K/Akt/mTOR&FoxO1 signal pathways, Biotechnol Lett, 36, 2417, 10.1007/s10529-014-1617-z · DOI
- Consitt, 2010, Peroxisome proliferator-activated receptor-gamma coactivator-1alpha overexpression increases lipid oxidation in myocytes from extremely obese individuals, Diabetes, 59, 1407, 10.2337/db09-1704 · DOI · Paper page
- Pauly, 2015, Combined Strategies for Maintaining Skeletal Muscle Mass and Function in Aging: Myostatin Inactivation and AICAR-Associated Oxidative Metabolism Induction, J Gerontol A Biol Sci Med Sci, 70, 1077, 10.1093/gerona/glu147 · DOI
- Takahashi, 2014, Myostatin alters glucose transporter-4 (GLUT4) expression in bovine skeletal muscles and myoblasts isolated from double-muscled (DM) and normal-muscled (NM) Japanese shorthorn cattle, Domest Anim Endocrinol, 48, 62, 10.1016/j.domaniend.2014.01.007 · DOI
- Rodriguez, 2017, Crosstalk between adipokines and myokines in fat browning, Acta Physiol (Oxf), 219, 362, 10.1111/apha.12686 · DOI · Paper page
- Cinti, 2012, The adipose organ at a glance, Dis Model Mech, 5, 588, 10.1242/dmm.009662 · DOI · Paper page
- Yoneshiro, 2011, Age-related decrease in coldactivated brown adipose tissue and accumulation of body fat in healthy humans, Obesity (Silver Spring), 19, 1755, 10.1038/oby.2011.125 · DOI · Paper page
- Yang, 2003, Reduced expression of FOXC2 and brown adipogenic genes in human subjects with insulin resistance, Obes Res, 11, 1182, 10.1038/oby.2003.163 · DOI · Paper page
- Chondronikola, 2014, Brown adipose tissue improves whole-body glucose homeostasis and insulin sensitivity in humans, Diabetes, 63, 4089, 10.2337/db14-0746 · DOI · Paper page
- Choi, 2011, Increased energy expenditure and leptin sensitivity account for low fat mass in myostatin-deficient mice, Am J Physiol Endocrinol Metab, 300, 1031, 10.1152/ajpendo.00656.2010 · DOI · Paper page
- Kalinkovich, 2015, Sarcopenia—The search for emerging biomarkers, Ageing Res Rev, 22, 58, 10.1016/j.arr.2015.05.001 · DOI · Paper page
Cited by
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Sarcopenic obesity in older adults: a clinical overview
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00943-z · Cited by 355
“While inhibition of myostatin leads to muscle cell hyperplasia and hypertrophy, suppresses irisin and downregulates pro-inflammatory cytokines, it may also have beneficial effects on metabolism, adiposity and insulin sensitivity 220 .”
Metabolic Syndrome and Sarcopenia
Nishikawa, H., Asai, A., Fukunishi, S., Nishiguchi, S., & Higuchi, K. (2021) · Nutrients · doi:10.3390/nu13103519 · Cited by 321
Sarcopenic Obesity: Epidemiologic Evidence, Pathophysiology, and Therapeutic Perspectives
Koliaki, C., Liatis, S., Dalamaga, M., & Kokkinos, A. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00359-9 · Cited by 176
Zamboni, M., Rubele, S., & Rossi, A. P. (2019) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000519 · Cited by 173
Metadata
- Authors
- Consitt, L. A., & Clark, B. C.
- Venue
- The Journal of Frailty & Aging
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 7
- Issue
- 1
- Pages
- 21-27
- ISSN
- 2260-1341 (ISSN-L)
- OpenAlex
- W2897010519
- Cited by
- 113
- References
- 22
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 2454 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.